Embla Medical hfOSSFF 92 Days Payable is 34.12 as of Mar. 2026, which is 5% below its 10-year median of 35.87. GuruFocus rates OSSFF with a GF Score™ of 92/100 and a GF Value™ of $5.49. The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Embla Medical hf ranks worse than 80.13% on this metric.
The historical rank and industry rank for Embla Medical hf's Days Payable or its related term are showing as below:
OSSFF'
s Days Payable Range Over the Past 10 Years
Min: 31.42 Med: 35.87 Max: 40.87
Current: 34.67
During the past 13 years, Embla Medical hf's highest Days Payable was 40.87. The lowest was 31.42. And the median was 35.87.
OSSFF's Days Payable is ranked worse than 80.13% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs OSSFF: 34.67
Embla Medical hf's Days Payable
declined
from Mar. 2025 (37.75) to Mar. 2026 (34.12).
It may suggest that Embla Medical hfaccelerated paying its suppliers.
Embla Medical hf Days Payable Related Terms
Embla Medical hf Days Payable Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Embla Medical hf's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's Days Payable distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Embla Medical hf's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embla Medical hf (OSSFF) has a Days Payable of 34.12 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Embla Medical hf and its competitors. This is near median its historical median of 35.87. Over the past decade, Embla Medical hf's Days Payable has ranged from 31.42 to 40.87. According to the industry distribution chart, Embla Medical hf ranks #637 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 80.1%.
Is Embla Medical hf's Days Payable too high?
Embla Medical hf's current Days Payable of 34.12 is near median its 10-year median of 35.87. Over the past 10 years, this metric has ranged from a low of 31.42 to a high of 40.87. The Medical Devices & Instruments industry median Days Payable is 67.87. Embla Medical hf's value of 34.12 is 49.7% below this industry median. Based on the distribution chart, Embla Medical hf ranks #637 out of 795 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Embla Medical hf has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #637 out of 795 companies for Days Payable. This places Embla Medical hf in the lower half of its industry. The industry median Days Payable is 67.87. Embla Medical hf's value of 34.12 is 49.7% below this benchmark. Historically, Embla Medical hf's own Days Payable has ranged from 31.42 to 40.87 over the past decade. While the company's 10-year median is 35.87 vs. the industry median of 67.87, Embla Medical hf has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current Days Payable of 34.12 is 49.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current Days Payable is 34.12, which is near median its own 10-year median of 35.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current Days Payable of 34.12. The stock's GF Value™ is $5.49, compared to a current price of $4.15 — trading 24.4% below its estimated fair value. The current Days Payable is 34.12, which is near median its 10-year median of 35.87 and 49.7% below the Medical Devices & Instruments industry median of 67.87. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current Days Payable is 34.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.15 is trading 24.4% below its estimated GF Value™ of $5.49.
Key valuation signals for OSSFF:
Days Payable: 34.12 (near median its 10-year median of 35.87)
GF Value™: $5.49 vs. price of $4.15 (24.4% below fair value)
Industry Position: 49.7% below the Medical Devices & Instruments median (#637 of 795)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OSSFF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
